Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jul 1;10(13):1867-71.
doi: 10.3748/wjg.v10.i13.1867.

Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery

Li Li  1 , Jia-Ling Huang, Qi-Cai Liu, Pei-Hong Wu, Ran-Yi Liu, Yi-Xin Zeng, Wen-Lin Huang
Affiliations

Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery

Li Li et al. World J Gastroenterol. .

Abstract

Aim: To investigate the expression of adenovirus-mediated human endostatin (Ad/hEndo) gene transfer and its effect on the growth of hepatocellular carcinoma (HCC) BEL-7402 xenografted tumors.

Methods: Immunohistochemistry analysis with an anti-endostatin antibody was preformed to detect endostatin protein expression in HCC BEL-7402 cells infected with Ad/hEndo. MTT assay was used to investigate the effects of Ad/hEndo on proliferation of human umbilical vein endothelial cells (HUVEC). Intra-tumoral injections of 1X10(9) pfu Ad/hEndo was given to treat BEL-7402 xenografted tumors in nude mice once weekly for 6 wk. Mice received injections of Ad/LacZ and DMEM were regarded as control groups. After intra-tumoral administration with Ad/hEndo, the endostatin mRNA expression in tumor tissue was analyzed by Northern blotting, and plasma endostatin levels were determined using enzyme-linked immunosorbent assay (ELISA).

Results: High level expression of endostatin gene was detected in the infected HCC BEL-7402 cells. Ad/hEndo significantly inhibited HUVEC cell proliferation by 57.2% at a multiplicity of infection (MOI) of 20. After 6-week treatment with Ad/hEndo, the growth of treated tumors was inhibited by 46.50% compared to the Ad/LacZ control group (t=2.729, P<0.05) and by 48.56% compared to the DMEM control group (t=2.485, P<0.05). The ratio of mean tumor volume in treated animals to mean tumor volume in the control animals (T:C ratio) was less than 50% after 24 d of treatment. Endostatin mRNA in tumor tissue was clearly demonstrated as a band of approximately 1.2 kb, which was the expected size of intact and functional endostatin. Plasma endostatin levels peaked at 87.52+/-8.34 ng/mL at d 3 after Ad/hEndo injection, which was significantly higher than the basal level (12.23+/-2.54 ng/mL). By d 7, plasma levels dropped to nearly half the peak level (40.34+/-4.80 ng/mL).

Conclusion: Adenovirus-mediated human endostatin gene can successfully express endogenous endostatin in vitro and in vivo, and significantly inhibit the growth of BEL-7402 xenografted liver tumors in nude mice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunohistochemistry analysis for endostatin pro-tein in vitro (× 100). Extensive positive staining was observed in the cytoplasm of transduced cells. This indicated that human endostatin gene mediated by recombinant adenovirus was highly expressed in BEL-7402 cells.
Figure 2
Figure 2
Effect of Ad/hEndo on the proliferation of HUVEC cells.
Figure 3
Figure 3
Effect of Ad/hEndo on growth of BEL-7402 xenografted liver tumors.
Figure 4
Figure 4
Northern blotting of endostatin mRNA in vivo. Lanes 1-3: RNA extracted from tumors on d 1, 4 and 8 after Ad/hEndo injection, respectively; Lane 4: RNA extracted from control tumors injected with DMEM.
Figure 5
Figure 5
Detection of endostatin concentration in plasma by ELISA.
Figure 6
Figure 6
Pathological changes of liver 1 wk after 6 wk of treatment with Ad/hEndo (HE, original magnification: × 200).
See this image and copyright information in PMC

References

    1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4–6. - PubMed
    1. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757–1763. - PubMed
    1. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999;284:808–812. - PubMed
    1. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–407. - PubMed
    1. Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol. 2003;9:1885–1891. - PMC - PubMed

Publication types

MeSH terms